Nazione: Irlanda
Lingua: inglese
Fonte: HPRA (Health Products Regulatory Authority)
Bovine herpes virus type 1 (BHV-1), strain difivac (gE-negative), modified live (attenuated) virus
Zoetis Belgium S.A.
QI02AD01
Bovine herpes virus type 1 (BHV-1), strain difivac (gE-negative), modified live (attenuated) virus
.
Lyophilisate and solvent for suspension for injection
POM (E): Prescription Only Exempt as defined in relevant national legislation
Cattle
bovine rhinotracheitis virus (IBR)
Immunological - Live Vaccine
Authorised
2013-12-09
1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rispoval IBR-Marker Live lyophilisate and diluent for suspension for injection for cattle 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2 ml dose contains: ACTIVE SUBSTANCE: FREEZE-DRIED PELLET: Bovine Herpes Virus type 1 (BoHV-1), strain Difivac (gE-negative), modified live (attenuated) virus min. 10 5.0 CCID 50 * max. 10 7.0 CCID 50 * * CCID 50 = Cell culture infective dose 50%. EXCIPIENTS: QUALITATIVE COMPOSITION OF EXCIPIENTS AND OTHER CONSTITUENTS QUANTITATIVE COMPOSITION IF THAT INFORMATION IS ESSENTIAL FOR PROPER ADMINISTRATION OF THE VETERINARY MEDICINAL PRODUCT FREEZE-DRIED PELLET: Dextran stabiliser solution Minimum essential medium with Earle´s salts HEPES 2M solution DILUENT: Water for injections _ _ 2 ml Lyophilisate: slightly coloured freeze-dried pellet. Diluent: clear, colourless solution. 3. CLINICAL INFORMATION 3.1 TARGET SPECIES Cattle. 3.2 INDICATIONS FOR USE FOR EACH TARGET SPECIES For active immunisation of cattle against Infectious Bovine Rhinotracheitis (IBR), to reduce virus shedding and clinical signs including, in female cattle, abortions associated with BoHV-1 infection. A reduction of abortion associated with BoHV-1 infections has been demonstrated during the second trimester of gestation upon challenge 28 days after vaccination. Vaccinated cattle can be differentiated from field virus infected animals due to the marker deletion, unless the cattle were previously vaccinated with a conventional vaccine or infected with field virus. Onset of immunity: 7 days following a single intranasal administration. 21 days following a single intramuscular administration. Duration of immunity following vaccination before 3 months of age: after intranasal vaccination of calves aged 2 weeks or older without maternally derived antibodies, immunity lasts until at least 3 months of age, when the animals should be revaccinated via intramuscular injection. A proportion of young calves may have maternally derived antibodies to BoHV-1, which may affect the im Leggi il documento completo